Unlocking New Frontiers in Breast Cancer Treatment: Synergistic Therapies and Clinical Advances by Atossa Therapeutics
In a significant stride toward innovative cancer treatment, Atossa Therapeutics, Inc. a clinical-stage biopharmaceutical firm, is making waves in the oncological community with its cutting-edge research and clinical trials aimed at improving outcomes for breast cancer patients. At the forefront of these efforts is their exploration of (Z)-endoxifen as a key therapeutic agent.
Atossa is set to present a remarkable advancement in breast cancer treatment at the upcoming 2024 San Antonio Breast Cancer Symposium. The company will unveil findings from a pioneering study that utilized insilico and chemical screening techniques to identify compounds that exhibit synergistic properties with (Z)-endoxifen. This promising discovery reveals the potential for these compounds to induce significant cell death in MCF-7 cells, a commonly studied breast cancer cell line, heralding an exciting avenue for developing combination therapies aimed at treating breast cancer.
Adding further momentum to these promising findings, Atossa Therapeutics, in collaboration with Quantum Leap Healthcare Collaborative, has launched an innovative clinical trial. The trial investigates the therapeutic potential of combining (Z)-endoxifen with abemaciclib (VERZENIO), a CDK 4/6 inhibitor marketed by Eli Lilly and Company. Encouragingly, the first patient has been successfully dosed, marking a significant milestone. This neoadjuvant treatment aims to provide a potent therapeutic option for women newly diagnosed with high-risk Estrogen Receptor positive (ER+) / Human Epidermal Growth Factor Receptor 2 negative (HER2-) breast cancer.
Meanwhile, Atossa s initiative to expand its research on (Z)-endoxifen continues with the completion of enrollment for the 12-patient 80mg pharmacokinetic run-in cohort of the Phase 2 EVANGELINE trial. This randomized non-inferiority trial, comparing Atossa’s selective estrogen receptor modulator (SERM) with exemestane plus goserelin, focuses on pre-menopausal women diagnosed with Grade 1 or 2 ER+ / HER2- breast cancer. The completion of this cohort signifies another critical step in Atossa s quest to refine and advance breast cancer therapy.
Atossa s continued dedication to addressing significant unmet medical needs in oncology through such sophisticated and targeted research demonstrates the convergence of science and strategy in combatting one of the most prevalent cancers affecting women worldwide. These ongoing endeavors not only promise to enhance therapeutic efficacy but also underscore Atossa s leadership and innovation in oncology clinical trials, potentially setting a new standard in breast cancer treatment.
Comments